Literature DB >> 3384919

Evaluation of rubella immune status by three commercial enzyme-linked immunosorbent assays.

P R Field1, D W Ho, A L Cunningham.   

Abstract

Three commercial indirect enzyme-linked immunosorbent assays (ELISAs) (Enzygnost-Rubella, RUBELISA, and ORTHO Rubella) were evaluated for the determination of immune status by testing 1,090 serum specimens, 410 of which were from nonimmune patients. In comparison with the standard reference technique, the hemagglutination inhibition (HAI) test, the sensitivities of ORTHO Rubella (100%) and Enzygnost-Rubella (99.26%) were excellent, whereas the sensitivity of RUBELISA (95.60%) was marginally lower because of the inability of this assay to detect antibody in 22% of the serum specimens with HAI titers of 10 and 11% of sera with HAI titers of 20. The specificity of all three systems was greater than 97%. There was a linear correlation between mean ELISA values and increasing HAI titers (r greater than or equal to 0.94). Both ORTHO Rubella and Enzygnost-Rubella were shown to be suitable replacements for the HAI test, provided that an equivocal zone is incorporated in the ORTHO system and only unheated sera are used in the Enzygnost system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3384919      PMCID: PMC266502          DOI: 10.1128/jcm.26.5.990-994.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  False positive rubella virus haemagglutination inhibition reactions: occurrence and disclosure.

Authors:  G Haukenes; H Blom
Journal:  Med Microbiol Immunol       Date:  1975       Impact factor: 3.402

2.  Rubella-specific IgM determination on heat-treated sera.

Authors:  C J Ronalds; A E Hardiman; P C Grint; H D Kangro
Journal:  Lancet       Date:  1985-11-09       Impact factor: 79.321

3.  Comparison of an enzyme-linked immunosorbent assay with indirect hemagglutination and hemagglutination inhibition for determination of rubella virus antibody: evaluation of immune status with commercial reagents in a clinical laboratory.

Authors:  A L Truant; B L Barksdale; T W Huber; L B Elliott
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

4.  Detection and differentiation of cytomegalovirus antibodies by radioimmunoassay.

Authors:  M A Jankowski; W Gut; E Nawrocka; M Kantoch
Journal:  J Virol Methods       Date:  1980       Impact factor: 2.014

5.  Evaluation of commercially available diagnostic test kits for rubella.

Authors:  G A Castellano; D L Madden; G T Hazzard; C S Cleghorn; D V Vails; A C Ley; N R Tzan; J L Sever
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

6.  Rubella-virus hemagglutination-inhibition test.

Authors:  G L Stewart; P D Parkman; H E Hopps; R D Douglas; J P Hamilton; H M Meyer
Journal:  N Engl J Med       Date:  1967-03-09       Impact factor: 91.245

7.  The derivation of a minimum immune titre of rubella haemagglutination-inhibition (HI) antibody. A Public Health Laboratory Service collaborative survey.

Authors:  C M Bradstreet; B Kirkwood; J R Pattison; J O Tobin
Journal:  J Hyg (Lond)       Date:  1978-12

8.  Antigen requirements, sensitivity, and specificity of enzyme immunoassays for measles and rubella viral antibodies.

Authors:  B Forghani; N J Schmidt
Journal:  J Clin Microbiol       Date:  1979-06       Impact factor: 5.948

9.  Evaluation of solid-phase enzyme-immunoassay procedure in immunity surveys and diagnosis of rubella.

Authors:  A Vaheri; E M Salonen
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

10.  Comparison of the sensitivity of ELISA and the haemagglutination-inhibition test for routine diagnosis of rubella.

Authors:  M Vejtorp; J Leerhoy
Journal:  Acta Pathol Microbiol Scand B       Date:  1980-12
View more
  8 in total

1.  Multicenter evaluation of five commercial rubella virus immunoglobulin G kits which report in international units per milliliter.

Authors:  W Dimech; A Bettoli; D Eckert; B Francis; J Hamblin; T Kerr; C Ryan; I Skurrie
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Acute Rubella Virus Infection among Women with Spontaneous Abortion in Mwanza City, Tanzania.

Authors:  Lukombodzo Lulandala; Mariam M Mirambo; Dismas Matovelo; Balthazar Gumodoka; Stephen E Mshana
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Detection of rubella-specific immunoglobulin G: comparison of the enzyme-linked immunosorbent assay and an automated microparticle enzyme immunoassay (IMx).

Authors:  I J Skurrie; J L Head; S M Garland
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

4.  Rubella Seromarkers and Determinants of Infection among Tanzanian Children and Adolescents in Prevaccination Era: Are We in the Right Track?

Authors:  Mariam M Mirambo; Said Aboud; Uwe Groß; Mtebe Majigo; Martha F Mushi; Stephen E Mshana
Journal:  Int J Prev Med       Date:  2017-01-23

5.  Magnitude of the Cytomegalovirus infection among pregnant women attending antenatal clinics in the city of Mwanza, Tanzania.

Authors:  Elieza Chibwe; Mariam M Mirambo; Albert Kihunrwa; Stephen E Mshana
Journal:  BMC Res Notes       Date:  2017-09-20

6.  Low humoral responses to human cytomegalovirus is associated with immunological treatment failure among HIV infected patients on highly active antiretroviral therapy.

Authors:  Mariam Mwinjuma Mirambo; Ndealilia Senyaeli; Stephen Eliatosha Mshana
Journal:  Pan Afr Med J       Date:  2017-10-10

7.  Acute human cytomegalovirus infection among voluntary blood donors in the Lake Victoria zone blood transfusion centre: should it be considered in screening?

Authors:  Erius Tebuka; Ruharara D Fulgence; Bertrand Msemwa; Vitus Silago; Stephen E Mshana; Mariam M Mirambo
Journal:  Afr Health Sci       Date:  2019-09       Impact factor: 0.927

8.  Serological evidence of acute rubella infection among under-fives in Mwanza: a threat to increasing rates of congenital rubella syndrome in Tanzania.

Authors:  Mariam M Mirambo; Said Aboud; Martha F Mushi; Mwanaisha Seugendo; Mtebe Majigo; Uwe Groß; Stephen E Mshana
Journal:  Ital J Pediatr       Date:  2016-05-25       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.